Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.

  title={Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.},
  author={Gero H{\"u}tter and Daniel Nowak and Maximilian Mossner and Susanne Ganepola and Arne M{\"u}ssig and Kristina Allers and Thomas Schneider and J{\"o}rg Hofmann and Claudia Kücherer and Olga Blau and Igor Wolfgang Blau and Wolf-Karsten Hofmann and Eckhard Thiel},
  journal={The New England journal of medicine},
  volume={360 7},
Infection with the human immunodeficiency virus type 1 (HIV-1) requires the presence of a CD4 receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Homozygosity for a 32-bp deletion in the CCR5 allele provides resistance against HIV-1 acquisition. We transplanted stem cells from a donor who was homozygous for CCR5 delta32 in a patient with acute myeloid leukemia and HIV-1 infection. The patient remained without viral rebound 20 months after transplantation and… 

Figures from this paper

Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation.

To the Editor: Infection with the human immunodeficiency virus (HIV) requires entry into target cells by binding of the viral envelope to the CD4 receptor and to either the chemokine (C-C motif)

Transplantation of CCR5-Δ32/Δ32 Stem Cells May Cure HIV Infection

A successful hematopoietic stem cell transplantation in an HIV-1 infected patient is described by transferring donor derived cells with a natural resistance against HIV infection (CCR5-delta 32 deletion); the patient is more than 6 years after allogeneic transplantation without requirement of any antiretroviral treatment.

CCR5 as a Natural and Modulated Target for Inhibition of HIV

A dual therapeutic anti-HIV lentiviral vector that down-regulates CCR5 and inhibits HIV-1 fusion via cell surface expression of the gp41-derived peptide, C46, is developed and is being tested in Phase I/II trials by engineering HIV-resistant hematopoietic cells.

HIV-1 cure after CCR5Δ32/Δ32 allogeneic hematopoietic stem cell transplantation

    Medicine, Biology
    Nature Medicine
  • 2023
Four years after analytic treatment interruption (ATI), the absence of viral rebound and the lack of immunological correlates of HIV-1 antigen persistence provide convincing evidence for HIV- 1 cure.

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.

Successful reconstitution of CD4(+) T cells at the systemic level as well as in the gut mucosal immune system after CCR5Δ32/Δ 32 stem cell transplantation is demonstrated, suggesting that cure of HIV has been achieved in this patient.

Hematopoietic Stem Cell-Based Therapy for HIV Disease: A Role for Regulatory T Cells

Insight and understanding of the effect of deleting the chemokine receptor CCR5 in T cells, and its interplay with immune regulation of Human Immunodeficiency Virus type–1, is developed to enable a novel technology platform to cure HIV disease.

Transplantation of selected or transgenic blood stem cells – a future treatment for HIV/AIDS?

Improvement of HIV-1 therapy that interferes with the entry mechanism seems to be a promising approach in HIV- 1-infected patients with no matching CCR5-delta32 deleted donor.

Cure of HIV-Infected Leukemia Patients with Cord Blood Transplantation

More than forty years after the onset of the HIV pandemic the disease has not been cured using Highly Active Antiretroviral Treatment (HAART), by gene therapy, or by Hematopoietic Cell

CCR5 as a Novel Cell and Gene Therapy Strategies Based on Induction of Resistance to HIV

Novel treatment strategies for HIV-1 infected patient by CCR5 gene targeted therapy are considered, including zinc finger nuclease (ZFN) eliminated some problems of Berlin and Boston patients by site-specific C CR5 gene modification.

R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy

It is suggested that potent antiretroviral therapy produces the conditions necessary for the gradual emergence of X4 variants in cellular reservoirs.

Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART

The coexistence of numerous HIV-1 quasispecies with different resistance genotypes and coreceptor use in cellular reservoirs may be relevant for future antiretroviral treatment strategies.

Could bone marrow transplantation cure AIDS?: review.

Review of the literature on syngeneic or allogeneic bone marrow transplantation in patients infected with HIV and in patients with acquired immune deficiency syndrome (AIDS) finds protection of repopulating cells from infection could be achieved by a combination of antiretroviral agents and gene therapy strategies.

Treatment with CCR5 antagonists: which patient may have a benefit?

MVR is not licensed for treatment naive patients but it has a high potential for further development in this patient group and shows better immunological reconstitution than efavirenz, and will be of benefit for patients in various treatment situations and regions.

Transfer and persistence of viral antibody-producing cells in bone marrow transplantation.

The findings indicate that donor and recipient memory cells are susceptible to the conditioning regimen or to the treatment that follows transplantation, and transferred immunity of long duration was seen; this finding indicated the occasional engraftment of memory cells.

CD8+ T-cell responses to different HIV proteins have discordant associations with viral load

A comprehensive analysis of the 160 dominant CD8+ T-cell responses in 578 untreated HIV-infected individuals from KwaZulu-Natal, South Africa suggested the existence of both effective immune responses and responses lacking demonstrable biological impact in chronic HIV infection.

Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection

Transfection studies have shown that longer 28-mer short hairpin siRNAs are very effective in gene downregulation as assessed by fluorescence-activated cell sorting and transcript quantitation by quantitative real-time polymerase chain reaction, and theseSiRNAs conferred strong antiviral protection during viral challenge.

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

The data suggest that CMV infection and disease rates are elevated in high-risk patients with delayed CMV-specific T- cell immune reconstitution and lower in those with early recovery of T-cell immunity.